Work

HIV-1 envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infection

Year: 2023

Type: article

Study design: Observational Study

Abstract: We studied the relationship between viral diversity and susceptibility to broadly neutralizing antibodies (bNAbs) in longitudinal plasma and peripheral blood mononuclear cells from 89 people with HIV who initiated antiretroviral therapy (ART) during acute and early HIV-1 infection (AEHI). HIV-1 diversity and predicted bNAb susceptibility were comparable across AEHI. Diversity evolution was not observed during ART, suggesting (pro)viruses at initiation or during treatment may identify individuals with susceptible virus for bNAb interventional trials.

Source: AIDS

DOI: 10.1097/qad.0000000000003792

Authors: Laurie A. VanderVeen, Lisa Selzer, Brian Moldt, Aiyappa Parvangada, Jiani Li, Jintanat Ananworanich, Trevor A. Crowell, Joseph J. Eron, Eric S. Daar, Richard Haubrich, Romas Geleziunas, Joshua Cyktor, John W. Mellors, Christian Callebaut

Institutions: Gilead Sciences (United States), GlaxoSmithKline (Belgium), Amsterdam Institute for Global Health and Development, Amsterdam University Medical Centers, Henry M. Jackson Foundation, Walter Reed Army Institute of Research, University of North Carolina at Chapel Hill, University of California, Los Angeles, The Lundquist Institute, Harbor–UCLA Medical Center, University of Pittsburgh

Language: English

Topic: HIV Research and Treatment

Subfield: Virology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funders: U.S. Department of Defense, Henry M. Jackson Foundation, National Institutes of Health, U.S. Army, National Institute of Allergy and Infectious Diseases

Awards: G1050281965, G2127051194, G6186512954, G857487509, Statistical and Data Management Center (SDMC), Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG), University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit

OpenAlex ID: W4392255304

FWCI: 0.947

Cites: 22

Cited by: 8

Related to: 10